MX343328B - Assays for the detection of anti-tnf drugs and autoantibodies. - Google Patents

Assays for the detection of anti-tnf drugs and autoantibodies.

Info

Publication number
MX343328B
MX343328B MX2014002586A MX2014002586A MX343328B MX 343328 B MX343328 B MX 343328B MX 2014002586 A MX2014002586 A MX 2014002586A MX 2014002586 A MX2014002586 A MX 2014002586A MX 343328 B MX343328 B MX 343328B
Authority
MX
Mexico
Prior art keywords
autoantibodies
assays
detection
tnf drugs
level
Prior art date
Application number
MX2014002586A
Other languages
Spanish (es)
Inventor
Sharat Singh
Shui Long Wang
Linda Ohrmund
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX343328B publication Critical patent/MX343328B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

The present invention provides assays for detecting and measuring the presence or level of anti-TNFa drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFa drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
MX2014002586A 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies. MX343328B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25504809P 2009-10-26 2009-10-26
US26287709P 2009-11-19 2009-11-19
US32463510P 2010-04-15 2010-04-15
US34556710P 2010-05-17 2010-05-17
US35126910P 2010-06-03 2010-06-03
US38967210P 2010-10-04 2010-10-04
US39358110P 2010-10-15 2010-10-15
PCT/US2010/054125 WO2011056590A1 (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies

Publications (1)

Publication Number Publication Date
MX343328B true MX343328B (en) 2016-11-01

Family

ID=43618083

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004877A MX2012004877A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies.
MX2014002586A MX343328B (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012004877A MX2012004877A (en) 2009-10-26 2010-10-26 Assays for the detection of anti-tnf drugs and autoantibodies.

Country Status (15)

Country Link
US (5) US8574855B2 (en)
EP (1) EP2494352B1 (en)
JP (3) JP5697677B2 (en)
KR (2) KR101761541B1 (en)
CN (2) CN102695955B (en)
AU (4) AU2010315547C1 (en)
BR (1) BR112012009855A2 (en)
CA (2) CA2778454C (en)
ES (1) ES2796530T3 (en)
IL (2) IL219315B (en)
MX (2) MX2012004877A (en)
NZ (3) NZ706187A (en)
RU (2) RU2015148676A (en)
WO (1) WO2011056590A1 (en)
ZA (2) ZA201203717B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2261230T3 (en) 2002-09-11 2017-06-12 Chugai Pharmaceutical Co Ltd Method of Protein Purification.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BR112012009855A2 (en) 2009-10-26 2018-06-26 Prometheus Laboratoires Inc methods for determining an effective amount of a drug, for optimizing therapy and / or reducing drug toxicity, for determining the presence or level of a drug, for optimizing the therapeutic amount of a drug, and for determining the presence or level of a drug. an autoantibody for a drug, and kit
CA2815026C (en) 2010-10-18 2018-11-20 Nestec S.A. Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) * 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
BR112013028808A2 (en) 2011-05-10 2016-09-06 Nestec Sa Disease Activity Profile Characterization Methods for Personalized Therapy Management
RU2013158256A (en) 2011-07-06 2015-07-10 Нестек С.А. ANALYSIS FOR DETECTING NEUTRALIZING AUTOANTIBODIES FOR BIOLOGICAL THERAPY TNFα
WO2013080050A2 (en) * 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
CN104136923B (en) 2012-03-08 2016-08-24 霍夫曼-拉罗奇有限公司 For characterizing the multiple chromatography-method of immunity of circulating immune complex
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US10132736B2 (en) 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
WO2014046474A2 (en) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease
KR101501375B1 (en) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 Composition for preventing or treating inflammatory bowel disease comprising metformin as an active ingredient
ES2771127T3 (en) 2012-10-05 2020-07-06 Prometheus Biosciences Inc Methods to predict and monitor mucosa healing
BR112015012482A2 (en) * 2012-11-30 2017-07-11 Nestec Sa Assays for detecting neutralizing autoantibodies to biological therapy
EP2954329A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2997371B1 (en) * 2013-05-16 2018-11-07 University of Pretoria A method of diagnosing tuberculosis
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
CA2965095A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
MX2017006959A (en) 2014-12-02 2017-08-10 Nestec Sa Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease.
EP3536705A1 (en) 2014-12-05 2019-09-11 Société des Produits Nestlé S.A. Isolated soluble alpha-4 integrin, beta-7 integrin and alpha-4/beta-7 heterodimer integrin
CN107110853A (en) * 2015-01-09 2017-08-29 阿通诺米斯公司 Determine the general determination method of the amount of TNF α depressant and its corresponding anti-medicine antibody
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
ES2716900T3 (en) * 2015-11-06 2019-06-17 Promise Advanced Proteomics A method to quantify anti-TNF antibodies
EP3165922B1 (en) 2015-11-06 2020-06-17 Promise Proteomics A method for quantifying therapeutic antibodies
WO2017201142A1 (en) * 2016-05-17 2017-11-23 Memorial Sloan Kettering Cancer Center Treatment of lung adenocarcinoma
CN109791142B (en) * 2016-07-08 2022-11-29 W 健康公司 Universal assay for determining the amount of a therapeutic monoclonal antibody and its corresponding anti-drug antibody in a sample
CA3078779A1 (en) 2017-10-10 2019-04-18 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
EP3514541A1 (en) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Method of quantitative determination of a therapeutical tnf-alpha inhibitor
CN112313511B (en) * 2018-04-20 2024-08-09 詹森生物科技公司 Chromatographic column identification in manufacturing methods for preparing anti-IL 12/IL23 antibody compositions
EP3935396A1 (en) * 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
KR102562006B1 (en) 2020-11-09 2023-08-02 바디텍메드(주) A rapid detection kit for monitoring anti-tnf alpha drug

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US4459359A (en) 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
FR2590674B1 (en) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med NEW DIAGNOSTIC REAGENTS
DE3631229A1 (en) 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
EP0440044A1 (en) 1990-01-31 1991-08-07 Abbott Laboratories Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing
US5094740A (en) 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5582998A (en) 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
JPH0566222A (en) 1991-09-09 1993-03-19 Tosoh Corp Material analyzing method
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0642021B1 (en) 1993-09-07 2000-11-02 Wako Pure Chemical Industries Ltd Process for measuring complement activity and reagent used therefor
JPH07110331A (en) * 1993-09-07 1995-04-25 Wako Pure Chem Ind Ltd Human complement value measuring method and reagent component for measuring the value
JPH07140144A (en) 1993-11-19 1995-06-02 S R L:Kk Method for measuring allergen specific ige antibody and antigen-antibody complex
EP1298144A3 (en) 1994-12-28 2006-05-31 University of Kentucky Research Foundation Murine monoclonal anti-idiotype antibody 3H1
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
JP3718435B2 (en) * 1996-08-12 2005-11-24 積水化学工業株式会社 Cell function measuring container and cell function measuring method
EP0882984B1 (en) 1996-08-12 2010-10-06 Sekisui Kagaku Kogyo Kabushiki Kaisha Containers and kits for the determination of cell functions, and method for the determination thereof
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AU766149B2 (en) * 1998-10-31 2003-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variants of humanized anti-carcinoma monoclonal antibody CC49
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
DE19858777B4 (en) * 1998-12-18 2006-07-27 Delta Biotechnology Ltd. Process for the partial or complete separation of glycosylated and non-glycosylated proteins
MXPA02005604A (en) * 1999-12-06 2004-09-10 Leo Pharma As AMINOBENZOPHENONES AS INHIBITORS OF IL 1bgr; AND TNF agr;.
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
EP1238077A1 (en) 1999-12-16 2002-09-11 Amgen Inc., Tnfr/opg-like molecules and uses thereof
UA81743C2 (en) * 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
ATE476654T1 (en) 2001-03-02 2010-08-15 Activx Biosciences Inc PROTEIN PROFILING PLATFORM
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003016909A1 (en) 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample
WO2003042247A2 (en) 2001-11-12 2003-05-22 Merck Patent Gmbh Modified anti-tnf alpha antibody
EP1470160A2 (en) 2001-12-05 2004-10-27 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
AU2003258036A1 (en) 2002-08-01 2004-02-23 Wyeth Methods and reagents relating to inflammation and apoptosis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
KR20070008501A (en) * 2003-08-01 2007-01-17 암젠 인코퍼레이티드 Crystalline tumor necrosis factor receptor 2 polypeptides
EP1660538A1 (en) 2003-08-14 2006-05-31 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
CA2572263A1 (en) 2004-06-30 2006-01-12 Centocor, Inc. Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
RU2007147426A (en) 2005-05-20 2009-06-27 Дженентек, Инк. (Us) PRELIMINARY PROCESSING OF A BIOLOGICAL SAMPLE Taken From An INDIVIDUAL WITH AN AUTOIMMUNE DISEASE
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
EP1910836B1 (en) 2005-07-21 2014-11-26 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
US20090162374A1 (en) 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
US7542502B2 (en) 2005-09-27 2009-06-02 Cymer, Inc. Thermal-expansion tolerant, preionizer electrode for a gas discharge laser
JP2009514977A (en) * 2005-11-08 2009-04-09 メダレックス インコーポレーティッド TNF-α blocking agent treatment method for enteritis associated with treatment with immunostimulatory therapeutic antibody
JP2007147367A (en) 2005-11-25 2007-06-14 Sekisui Chem Co Ltd Method of measuring cytokine production ability
DE102005057920A1 (en) 2005-12-02 2007-06-28 Strohner, Pavel, Dr. Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a therapeutic antibody directed against the analyte in samples
US20100130367A1 (en) 2006-07-11 2010-05-27 Drexel University Methods of Quantitatively Assessing Inflammation with Biosensing Nanoparticles
US20080286774A1 (en) 2007-05-16 2008-11-20 The Regents Of The University Of California Real-time individualized therapy evaluation
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009042114A2 (en) * 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2011510291A (en) * 2008-01-15 2011-03-31 スティヒティンク サンクイン ブロイドフォーツィーニンク Methods and kits for detecting antibodies against therapeutic antibodies
US20090234202A1 (en) 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
BR112012009855A2 (en) 2009-10-26 2018-06-26 Prometheus Laboratoires Inc methods for determining an effective amount of a drug, for optimizing therapy and / or reducing drug toxicity, for determining the presence or level of a drug, for optimizing the therapeutic amount of a drug, and for determining the presence or level of a drug. an autoantibody for a drug, and kit
CA2815026C (en) 2010-10-18 2018-11-20 Nestec S.A. Methods for determining anti-drug antibody isotypes
EP2676137B1 (en) 2011-02-17 2014-12-31 Nestec S.A. Assays for detecting autoantibodies to anti-tnf drugs
RU2013158256A (en) 2011-07-06 2015-07-10 Нестек С.А. ANALYSIS FOR DETECTING NEUTRALIZING AUTOANTIBODIES FOR BIOLOGICAL THERAPY TNFα
US20130266963A1 (en) 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
US20130295685A1 (en) 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
BR112015012482A2 (en) 2012-11-30 2017-07-11 Nestec Sa Assays for detecting neutralizing autoantibodies to biological therapy
EP3536705A1 (en) 2014-12-05 2019-09-11 Société des Produits Nestlé S.A. Isolated soluble alpha-4 integrin, beta-7 integrin and alpha-4/beta-7 heterodimer integrin

Also Published As

Publication number Publication date
KR101761541B1 (en) 2017-07-26
NZ706187A (en) 2016-09-30
US9506920B2 (en) 2016-11-29
EP2494352B1 (en) 2020-04-08
MX2012004877A (en) 2012-05-23
US20120329172A1 (en) 2012-12-27
KR20120108978A (en) 2012-10-05
NZ599456A (en) 2014-06-27
US20140057367A1 (en) 2014-02-27
JP5878253B2 (en) 2016-03-08
US20170184588A1 (en) 2017-06-29
IL256728A (en) 2018-04-09
US8865417B2 (en) 2014-10-21
AU2010315547C1 (en) 2015-06-04
WO2011056590A1 (en) 2011-05-12
KR20170088437A (en) 2017-08-01
AU2017213584A1 (en) 2017-08-31
KR101881714B1 (en) 2018-07-24
CA2778454C (en) 2021-03-02
JP2016106222A (en) 2016-06-16
US8574855B2 (en) 2013-11-05
BR112012009855A2 (en) 2018-06-26
RU2571489C2 (en) 2015-12-20
ES2796530T3 (en) 2020-11-27
AU2015202899B2 (en) 2017-06-01
JP6082831B2 (en) 2017-02-15
CN102695955B (en) 2015-03-18
CN104634955A (en) 2015-05-20
CA2778454A1 (en) 2011-05-12
NZ621655A (en) 2015-08-28
IL219315A0 (en) 2012-06-28
ZA201504548B (en) 2019-10-30
JP2015148616A (en) 2015-08-20
CN102695955A (en) 2012-09-26
JP5697677B2 (en) 2015-04-08
US20200018751A1 (en) 2020-01-16
IL219315B (en) 2018-01-31
RU2012121710A (en) 2013-12-10
AU2010315547B2 (en) 2015-03-05
US10386366B2 (en) 2019-08-20
RU2015148676A3 (en) 2019-06-18
AU2010315547A1 (en) 2012-05-10
US20150024404A1 (en) 2015-01-22
JP2013508739A (en) 2013-03-07
AU2015202899A1 (en) 2015-06-18
AU2019205009A1 (en) 2019-08-01
AU2017213584B2 (en) 2019-04-18
EP2494352A1 (en) 2012-09-05
RU2015148676A (en) 2019-01-15
CN104634955B (en) 2016-09-14
ZA201203717B (en) 2018-11-28
CA3108458A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
MX343328B (en) Assays for the detection of anti-tnf drugs and autoantibodies.
MX343327B (en) ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFa DRUGS.
MX349561B (en) Method for detecting nucleosomes containing histone variants.
TR201904386T4 (en) Method for detecting nucleosomes containing nucleotides.
WO2013030578A3 (en) Method for detecting nucleosomes
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
ATE472110T1 (en) SENSOR DEVICE AND METHOD FOR DETECTING MAGNETIC PARTICLES
EP2419733A4 (en) Methods and devices for detecting the presence of an analyte in a sample
MX356986B (en) Method for detecting nucleosome adducts.
MX357119B (en) Plasma micrornas for the detection of early colorectal cancer.
MX343324B (en) Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha.
CO6680668A2 (en) Biomarker assays to detect or measure inhibition of tor kinase activity
FR2996673B1 (en) CAPACITIVE SENSOR FOR DETECTING THE PRESENCE OF AN OBJECT AND / OR AN INDIVIDUAL.
WO2011144948A3 (en) Detecting descented material
WO2011015602A3 (en) Lung cancer biomarkers
MX2015006852A (en) Assays for detecting neutralizing autoantibodies to biologic therapy.
FR2953292B1 (en) HYDROGEN SENSOR AND METHOD FOR DETECTING HYDROGEN CONCENTRATION.
EA201291396A1 (en) METHOD OF DETECTION OF MOLECULAR INTERACTIONS
GB201206977D0 (en) An enzyme detection device
WO2013086490A3 (en) Methods, apparatus, and sensors for tracing frac fluids in mineral formations, production waters, and the environment using magnetic particles
MX2012009908A (en) Assays and kits for serotyping pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits.
MX2016005313A (en) Detection of cleavage activity of an enzyme.
GB2470757B (en) Non invasive gas analysis
GB201314219D0 (en) Fluid collection and expulsion apparatus
WO2013101276A3 (en) Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway